Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
557 Neoadjuvant Camrelizumab in combination with albumin paclitaxel and cisplatin for patients with locally advanced esophageal squamous cell carcinoma (ESCC)
Compose a Response to This Article
Other responses
No responses have been published for this article.